Spironolactone and New-Onset Diabetes in Heart Failure: A Post Hoc Analysis of the TOPCAT Trial
{{output}}
Background: Evidence regarding the effect of mineralocorticoid receptor antagonist therapy on the risk of new-onset diabetes remains inconsistent. Objectives: ... ...
